These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 12002344)

  • 1. Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: identity of a potent new bisphosphonate analogue.
    Reinholz GG; Getz B; Sanders ES; Karpeisky MY; Padyukova NSh; Mikhailov SN; Ingle JN; Spelsberg TC
    Breast Cancer Res Treat; 2002 Feb; 71(3):257-68. PubMed ID: 12002344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts.
    Reinholz GG; Getz B; Pederson L; Sanders ES; Subramaniam M; Ingle JN; Spelsberg TC
    Cancer Res; 2000 Nov; 60(21):6001-7. PubMed ID: 11085520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells.
    Merrell MA; Wakchoure S; Lehenkari PP; Harris KW; Selander KS
    Eur J Pharmacol; 2007 Sep; 570(1-3):27-37. PubMed ID: 17640631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates.
    van beek E; Löwik C; van der Pluijm G; Papapoulos S
    J Bone Miner Res; 1999 May; 14(5):722-9. PubMed ID: 10320520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiated suppression of Dickkopf-1 in breast cancer by combined administration of the mevalonate pathway inhibitors zoledronic acid and statins.
    Göbel A; Browne AJ; Thiele S; Rauner M; Hofbauer LC; Rachner TD
    Breast Cancer Res Treat; 2015 Dec; 154(3):623-31. PubMed ID: 26515701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of two novel bisphosphonates on bone cells in vitro.
    Evans CE; Braidman IP
    Bone Miner; 1994 Aug; 26(2):95-107. PubMed ID: 7994190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone-Bound Bisphosphonates Inhibit Proliferation of Breast Cancer Cells.
    Park YE; Bava U; Lin JM; Cornish J; Naot D; Reid IR
    Calcif Tissue Int; 2019 Nov; 105(5):497-505. PubMed ID: 31324954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates modulate vital functions of human osteoblasts and affect their interactions with breast cancer cells.
    Kaiser T; Teufel I; Geiger K; Vater Y; Aicher WK; Klein G; Fehm T
    Breast Cancer Res Treat; 2013 Jul; 140(1):35-48. PubMed ID: 23807419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonates induce breast cancer cell death in vitro.
    Fromigue O; Lagneaux L; Body JJ
    J Bone Miner Res; 2000 Nov; 15(11):2211-21. PubMed ID: 11092402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of osteoblast function in vitro by aminobisphosphonates.
    Orriss IR; Key ML; Colston KW; Arnett TR
    J Cell Biochem; 2009 Jan; 106(1):109-18. PubMed ID: 19003973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway.
    Virtanen SS; Väänänen HK; Härkönen PL; Lakkakorpi PT
    Cancer Res; 2002 May; 62(9):2708-14. PubMed ID: 11980672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates: from the laboratory to the clinic and back again.
    Russell RG; Rogers MJ
    Bone; 1999 Jul; 25(1):97-106. PubMed ID: 10423031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
    Jagdev SP; Coleman RE; Shipman CM; Rostami-H A; Croucher PI
    Br J Cancer; 2001 Apr; 84(8):1126-34. PubMed ID: 11308265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells.
    Göbel A; Thiele S; Browne AJ; Rauner M; Zinna VM; Hofbauer LC; Rachner TD
    Cancer Lett; 2016 May; 375(1):162-171. PubMed ID: 26968247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dickkopf-1 is regulated by the mevalonate pathway in breast cancer.
    Rachner TD; Göbel A; Thiele S; Rauner M; Benad-Mehner P; Hadji P; Bauer T; Muders MH; Baretton GB; Jakob F; Ebert R; Bornhäuser M; Schem C; Hofbauer LC
    Breast Cancer Res; 2014 Feb; 16(1):R20. PubMed ID: 24528599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
    Shipman CM; Croucher PI; Russell RG; Helfrich MH; Rogers MJ
    Cancer Res; 1998 Dec; 58(23):5294-7. PubMed ID: 9850051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts.
    Kellinsalmi M; Mönkkönen H; Mönkkönen J; Leskelä HV; Parikka V; Hämäläinen M; Lehenkari P
    Basic Clin Pharmacol Toxicol; 2005 Dec; 97(6):382-91. PubMed ID: 16364054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts.
    Fromigué O; Body JJ
    J Endocrinol Invest; 2002 Jun; 25(6):539-46. PubMed ID: 12109626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppressive effects of N-bisphosphonate in osteoblastic cells mitigated by non-N-bisphosphonate but not by sodium-dependent phosphate cotransporter inhibitor.
    Baba TT; Miyazaki T; Ohara-Nemoto Y; Nemoto TK
    Cell Biochem Funct; 2019 Aug; 37(6):400-407. PubMed ID: 31328801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of phosphate transporters ameliorates the inflammatory and necrotic side effects of the nitrogen-containing bisphosphonate zoledronate in mice.
    Okada S; Kiyama T; Sato E; Tanaka Y; Oizumi T; Kuroishi T; Takahashi T; Sasaki K; Sugawara S; Endo Y
    Tohoku J Exp Med; 2013 Oct; 231(2):145-58. PubMed ID: 24140868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.